TBPH Theravance Corp: Enterprise Value to EBITDA Ratio

theravance.com (TBPH) - corporate logo

Geopolitical risks and patent complexities are weighing on Theravance Biopharma (TBPH), although the diversification of its respiratory portfolio and royalty streams stabilize the business. On the GURU.Markets platform, the EV/EBITDA valuation history helps balance these factors, with the metric holding around 70.75. Ultimately, while loyalty among COPD patients remains high, pricing pressure from generics is eroding the company's overall margins.

Theravance Biopharma Inc - TBPH Business Value to Operating Income Before Depreciation (period 11/23/2025 - 10/10/2026)

Comprehensive metric breakdowns and analytics for Theravance (TBPH)

General company analysis:Theravance Biopharma TBPH
Original product of Theravance Biopharma Inc

This ratio compares the total enterprise value, including net debt, to operating profit before depreciation and amortization, allowing for an assessment of the real value of assets regardless of the tax regime. By analyzing the EV/EBITDA metric of Theravance Biopharma (TBPH), an investor determines the efficiency of capitalizing the company's scientific achievements in respiratory therapy, where a strong reputation in pulmonology should convert into sustainable growth in operating cash flow.

Key competitors

Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals Inc - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company PLC) - EV/EBITDA Multiple|Company Value to EBITDA alvotech.com ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia (LQDA)|GLPG (Galapagos) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals Inc)|MNKD - Enterprise Value to EBITDA Ratio|AMPH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals Inc (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aquestive Therapeutics, Inc. (AQST) - EV/EBITDA Multiple|SCPH (scpharmaceuticals.com) - EV/EBITDA Multiple|TECX (tectonictx.com) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TNXP (Tonix Pharmaceuticals Holding Corp.)|EV/EBITDA Multiple SXT China (SXTC)|eupraxiapharma.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|invizyne.com - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ORMP (Oramed Pharmaceuticals Inc.)|ENTX: EV/EBITDA Multiple|MindWalk Holdings Inc. (HYFT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to Operating Income Before Depreciation CPIX (Cumberland Pharmaceuticals Inc.)|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Corporation|EV/EBITDA Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio